Founded in Franklin, United States, Pierian Biosciences is a diagnostic development and laboratory service company committed to advancing personalized cancer treatment. Their core mission is to deliver innovative, treatment-directing assays and analytical approaches that guide personalized medicine and translational science. The company offers products such as CHEMOINTEL™ and IMMUNOINTEL™, which provide specific, actionable information on the most appropriate chemotherapeutic, biologic, and immunotherapeutic treatments for cancer patients.
Pierian Biosciences has a notable leadership team and board of directors who bring extensive expertise in oncology and diagnostics. The company has achieved significant milestones in optimizing their technology platforms to enhance the quality of life for cancer patients through personalized treatment strategies. Their impact is evident in the improved clinical outcomes and tailored therapeutic approaches they provide, positioning them as a pivotal player in the personalized medicine landscape.